Shmuel A. Ben-Sasson
Corporate Officer/Principal chez The Hebrew University of Jerusalem
Profil
Shmuel A.
Ben-Sasson is the founder of Chiasma, Inc. (founded in 2001) and Raziel Therapeutics RT Ltd.
(founded in 2012).
Dr. Ben-Sasson is also the founder of Keryx Biopharmaceuticals, Inc. Currently, Dr. Ben-Sasson holds the position of Associate Professor-Experimental Medicine at The Hebrew University of Jerusalem.
Postes actifs de Shmuel A. Ben-Sasson
| Sociétés | Poste | Début |
|---|---|---|
| The Hebrew University of Jerusalem | Corporate Officer/Principal | - |
Anciens postes connus de Shmuel A. Ben-Sasson
| Sociétés | Poste | Fin |
|---|---|---|
| CHIASMA, INC. | Fondateur | - |
Raziel Therapeutics RT Ltd.
 Raziel Therapeutics RT Ltd. Pharmaceuticals: MajorHealth Technology Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel. | Fondateur | - |
| KERYX BIOPHARMACEUTICALS | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Chiasma, Inc.
 Chiasma, Inc. Pharmaceuticals: MajorHealth Technology Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. Its products include octreotide capsules. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Needham, MA. | Health Technology |
Raziel Therapeutics RT Ltd.
Raziel Therapeutics RT Ltd. Pharmaceuticals: MajorHealth Technology Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel. | Health Technology |
